Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe page now displays Revision: v3.5.2, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.5.0 has been added and revision v3.4.3 has been removed.SummaryDifference0.1%

- Check42 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision: v3.4.2 was added and the prior funding notice (v3.4.1) was removed; there are no changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedA government funding/status notice was added to the page footer and the site revision updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedAdded a glossary toggle. Made minor wording/casing updates to update log and footer metadata, and updated the page revision.SummaryDifference0.2%

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.